Owkin 解决了大众最担心的患者数据隐私问题，通过整合不同机构的多模态数据，加速生物标志物的发现，为精准医疗提供了可靠的决策依据，助力 ...

Owkin 解决了大众最担心的患者数据隐私问题，通过整合不同机构的多模态数据，加速生物标志物的发现，为精准医疗提供了可靠的决策依据，助力 ...

The global laboratory informatics market is experiencing a period of growth due to the acceleration of digital transformation and AI, as well as the rising use of data management tools in new markets ...

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical ...

Owkin’s solution is to bring academic and pharmaceutical industry researchers together in a federated research environment. Here, the company’s proprietary infrastructure and artificial ...

Artificial intelligence specialist Owkin has added another piece to its medical research portfolio with the launch of ...

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective ...

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

Owkin has announced a partnership with AstraZeneca to create an AI gBRCA pre-screening solution designed to identify ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...